Vanda Seeks Supreme Court Review on Lower Standard for Obviousness
Patently-O
JANUARY 23, 2024
Vanda Pharmaceuticals recently filed a petition for writ of certiorari , asking the Supreme Court to review a May 2023 decision by the Federal Circuit that invalidated claims from four Vanda patents covering methods of treating Non-24-Hour Sleep-Wake Disorder (“Non-24”) using the drug tasimelteon (Hetlioz). 398 (2007).
Let's personalize your content